Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 2 | 2018
Market Outlook
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-4 inhibitor Otezla. In recent years, multiple new therapies have been approved for the treatment of PsA. However, Xeljanz’s unique MOA, oral administration, and strong efficacy warrant the attention of both rheumatologists and dermatologists.
The PsA Emerging Therapies series includes three waves that will track the awareness, trial, and usage of Xeljanz since its approval in December 2017 for the treatment of PsA. In addition, the series will examine physician-anticipated future trends in PsA treatment,particularly Xeljanz uptake, as well as assess Pfizer’s promotional efforts.
Questions Answered
- What is U.S. rheumatologists’ and dermatologists’ awareness of, familiarity with, and perception of Xeljanz?
- What patients are being prescribed Xeljanz, what are the reasons for prescribing, and how satisfied are physicians with Xeljanz?
- How do prescribers and nonprescribers compare across key metrics?
- How do the trial and adoption of Xeljanz compare with that of other recently launched products in the autoimmune market?
Product Description
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product as well as the impact on current therapies and anticipated future trends. We also provide insight on promotional efforts, prescriber and nonprescriber profiles, and benchmarking agents against other launched agents.
